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The identification of the Kaposi's sarcoma (KS)-associated
herpesvirus (KSHV) as the viral etiologic agent for KS has
provided an opportunity to uncover its molecular patho-
genesis and to identify new therapeutic targets for this
neoplasm. The expression of only one KSHV gene, vGPCR,
is able to induce KS-like sarcomas in mice, suggesting that
vGPCR may be the viral gene responsible for the develop-
ment of KS.
Here, we demonstrate that dysregulation of Akt/TSC2/
mTOR by the KSHV vGPCR is essential for KS sarcom-
agenesis. In vitro, cells overexpressing vGPCR showed con-
stitutive signaling of Akt/TSC/mTOR.
Immunohistochemical analysis of vGPCR experimental
and human KS tissues revealed high levels of phosphor-
ylated Akt and S6 ribosomal protein. Of interest, the treat-
ment of allografts established upon injection of
endothelial cells overexpressing KSHV vGPCR with the
specific mTOR inhibitor, rapamycin, blocked tumor
growth, providing a molecular explanation of the efficacy
of rapamycin in the regression of KS lesions in patients
with iatrogenic KS. Moreover, a novel dual inhibitor of
PI3Kα and mTOR, PI-103, was able to inhibit vGPCR
tumorigenesis in vitro and in vivo. Exposure of vGPCR
expressing cells to this compound blocked the phosphor-
ylation of Akt, its downstream substrates, and mTOR sug-
gesting that combinatorial inhibition of mTOR and
p110α may represent an effective therapeutic alternative
for KS patients. All together, these results suggest that spe-
cific inhibitors of Akt/TSC/mTOR represent valuable ther-
apeutic alternatives for Kaposi's sarcoma.
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